Business Context and Reporting Period
Pavmed Inc. (PAVM) filed a Form 8-K on March 27, 2026, reporting the results of a Special Meeting of stockholders held on the same date. Approximately 54.1% of the voting power outstanding was present in person or by proxy.
Key Financial Metrics
This filing is a current report regarding corporate governance and capital structure actions. It does not contain revenue, profit, cash flow, margin, debt, or liquidity metrics. The filing text does not provide a clear value for these financial indicators.
Material Changes and Corporate Actions
Stockholders approved three significant proposals at the Special Meeting:
- Stock Issuance Approval: Approved the issuance of common stock upon conversion of 60,000 shares of Series D Convertible Preferred Stock and underlying warrants from a February 3, 2026 private placement. Also approved issuances pursuant to an Amended and Restated Senior Secured Convertible Note issued on the same date.
- Voting Results: 640,946 For; 72,380 Against; 5,055 Abstain.
- Charter Amendment: Approved an amendment to the Certificate of Incorporation to permit the removal of any director, with or without cause, by a majority vote of outstanding voting power. The amendment was filed with the Delaware Secretary of State and became effective March 27, 2026.
- Voting Results: 858,651 For; 60,825 Against; 6,042 Abstain.
- Equity Plan Amendment: Approved an increase to the 2014 Long-Term Incentive Equity Plan share pool by 1,500,000 shares, raising the total available shares from 213,517 to 1,713,517.
- Voting Results: 756,683 For; 162,305 Against; 6,530 Abstain.
Guidance, Outlook, and Risks
The filing does not contain management guidance, financial outlook, or specific risk factor disclosures beyond the standard incorporation by reference to the Definitive Proxy Statement filed on February 24, 2026. No unusual items or contingencies were disclosed in this specific report.
Investor Verification Checklist
- Verify the dilution impact of the approved Series D Preferred Stock conversion and Senior Secured Convertible Note issuances.
- Review the full text of the Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan (Exhibit 10.1) to understand vesting terms for the newly authorized 1.5 million shares.
- Confirm the effective date and legal implications of the new director removal provision in the amended Certificate of Incorporation.
- Consult the Definitive Proxy Statement (Schedule 14A) filed on February 24, 2026, for detailed descriptions of the stock issuances and plan amendments.